Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling

Molecular Neurodegeneration

David M Holtzman¹  Randall J Bateman¹  Bruce W Patterson²  Maia Parsadanian¹  Hong Jiang¹  Kristin R Wildsmith¹  Yuriy Pyatkivskyy¹  Jungsu Kim¹  Jacob M Basak¹ 

[1] Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, Saint Louis, Missouri, 63110, USA;Medicine, Saint Louis, Missouri, 63110, USA

关键词: Multiple reaction monitoring mass spectrometry;    ABCA1;    LDLR;    Protein turnover;    Kinetics;    Amyloid beta;    Apolipoprotein E;    Stable isotope;   

Others  :  863875
DOI  :  10.1186/1750-1326-7-14

 received in 2012-02-19, accepted in 2012-04-18,  发布年份 2012

【 摘 要 】

Background

Abnormal proteostasis due to alterations in protein turnover has been postulated to play a central role in several neurodegenerative diseases. Therefore, the development of techniques to quantify protein turnover in the brain is critical for understanding the pathogenic mechanisms of these diseases. We have developed a bolus stable isotope-labeling kinetics (SILK) technique coupled with multiple reaction monitoring mass spectrometry to measure the clearance of proteins in the mouse brain.

Results

Cohorts of mice were pulse labeled with ¹³ C₆-leucine and the brains were isolated after pre-determined time points. The extent of label incorporation was measured over time using mass spectrometry to measure the ratio of labeled to unlabeled apolipoprotein E (apoE) and amyloid β (Aβ). The fractional clearance rate (FCR) was then calculated by analyzing the time course of disappearance for the labeled protein species. To validate the technique, apoE clearance was measured in mice that overexpress the low-density lipoprotein receptor (LDLR). The FCR in these mice was 2.7-fold faster than wild-type mice. To demonstrate the potential of this technique for understanding the pathogenesis of neurodegenerative disease, we applied our SILK technique to determine the effect of ATP binding cassette A1 (ABCA1) on both apoE and Aβ clearance. ABCA1 had previously been shown to regulate both the amount of apoE in the brain, along with the extent of Aβ deposition, and represents a potential molecular target for lowering brain amyloid levels in Alzheimer's disease patients. The FCR of apoE was increased by 1.9- and 1.5-fold in mice that either lacked or overexpressed ABCA1, respectively. However, ABCA1 had no effect on the FCR of Aβ, suggesting that ABCA1 does not regulate Aβ metabolism in the brain.

Conclusions

Our SILK strategy represents a straightforward, cost-effective, and efficient method to measure the clearance of proteins in the mouse brain. We expect that this technique will be applicable to the study of protein dynamics in the pathogenesis of several neurodegenerative diseases, and could aid in the evaluation of novel therapeutic agents.

【 授权许可】

   
2012 Basak et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Ong SE, Mann M: Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 2005, 1:252-262.
• [2]Doherty MK, Beynon RJ: Protein turnover on the scale of the proteome. Expert Rev Proteomics 2006, 3:97-110.
• [3]Holtzman DM, Morris JC, Goate AM: Alzheimer’s disease: the challenge of the second century. Sci Transl Med 2011, 3:77sr71.
• [4]Goedert M: Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001, 2:492-501.
• [5]DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N: Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
• [6]Trojanowski JQ, Dickson D: Update on the neuropathological diagnosis of frontotemporal dementias. J Neuropathol Exp Neurol 2001, 60:1123-1126.
• [7]Balch WE, Morimoto RI, Dillin A, Kelly JW: Adapting proteostasis for disease intervention. Science 2008, 319:916-919.
• [8]Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ: Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 2010, 330:1774.
• [9]Wolfe RR, Chinkes DL: Isotope tracers in metabolic research : principles and practice of kinetic analysis. 2nd edition. Wiley-Liss, Hoboken; 2005.
• [10]Aebersold R, Mann M: Mass spectrometry-based proteomics. Nature 2003, 422:198-207.
• [11]Pratt JM, Petty J, Riba-Garcia I, Robertson DH, Gaskell SJ, Oliver SG, Beynon RJ: Dynamics of protein turnover, a missing dimension in proteomics. Mol Cell Proteomics 2002, 1:579-591.
• [12]Doherty MK, Hammond DE, Clague MJ, Gaskell SJ, Beynon RJ: Turnover of the human proteome: determination of protein intracellular stability by dynamic SILAC. J Proteome Res 2009, 8:104-112.
• [13]Schwanhausser B, Gossen M, Dittmar G, Selbach M: Global analysis of cellular protein translation by pulsed SILAC. Proteomics 2009, 9:205-209.
• [14]Doherty MK, Whitehead C, McCormack H, Gaskell SJ, Beynon RJ: Proteome dynamics in complex organisms: using stable isotopes to monitor individual protein turnover rates. Proteomics 2005, 5:522-533.
• [15]Price JC, Guan S, Burlingame A, Prusiner SB, Ghaemmaghami S: Analysis of proteome dynamics in the mouse brain. Proc Natl Acad Sci U S A 2010, 107:14508-14513.
• [16]Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM: Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006, 12:856-861.
• [17]Bateman RJ, Munsell LY, Chen X, Holtzman DM, Yarasheski KE: Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates. J Am Soc Mass Spectrom 2007, 18:997-1006.
• [18]Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, et al.: A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 2009, 66:48-54.
• [19]Mahley RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622-630.
• [20]Kim J, Basak JM, Holtzman DM: The role of apolipoprotein E in Alzheimer’s disease. Neuron 2009, 63:287-303.
• [21]Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV: ApoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 2008, 118:4002-4013.
• [22]Castellano JM, Kim J, Stewart FR, Jiang H, Demattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, et al.: Human apoE Isoforms Differentially Regulate Brain Amyloid-{beta} Peptide Clearance. Sci Transl Med 2011, 3:89ra57.
• [23]Ma J, Yee A, Brewer HB: Das S, Potter H: Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 1994, 372:92-94.
• [24]Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PT: Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci U S A 1995, 92:763-767.
• [25]Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, et al.: Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 1997, 17:263-264.
• [26]Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, Basak JM, Finn MB, Holtzman DM: Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. J Neurosci 2011, 31:18007-18012.
• [27]Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM: Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 2009, 64:632-644.
• [28]Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM: ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem 2004, 279:40987-40993.
• [29]Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL: Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem 2004, 279:41197-41207.
• [30]Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, et al.: Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 2008, 118:671-682.
• [31]Garlick PJ, McNurlan MA, Essen P, Wernerman J: Measurement of tissue protein synthesis rates in vivo: a critical analysis of contrasting methods. Am J Physiol 1994, 266:E287-E297.
• [32]Imoberdorf R, Garlick PJ, McNurlan MA, Casella GA, Peheim E, Turgay M, Bartsch P, Ballmer PE: Enhanced synthesis of albumin and fibrinogen at high altitude. J Appl Physiol 2001, 90:528-537.
• [33]Zhang XJ, Chinkes DL, Wolfe RR: Measurement of muscle protein fractional synthesis and breakdown rates from a pulse tracer injection. Am J Physiol Endocrinol Metab 2002, 283:E753-E764.
• [34]Smith QR, Momma S, Aoyagi M, Rapoport SI: Kinetics of neutral amino acid transport across the blood–brain barrier. J Neurochem 1987, 49:1651-1658.
• [35]Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M: Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002, 1:376-386.
• [36]Lusis AJ, Taylor BA, Quon D, Zollman S, LeBoeuf RC: Genetic factors controlling structure and expression of apolipoproteins B and E in mice. J Biol Chem 1987, 262:7594-7604.
• [37]Srivastava RA, Krul ES, Lin RC, Schonfeld G: Regulation of lipoprotein metabolism by estrogen in inbred strains of mice occurs primarily by posttranscriptional mechanisms. Mol Cell Biochem 1997, 173:161-168.
• [38]Brown MS, Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232:34-47.
• [39]Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF: The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 1999, 104:R25-R31.
• [40]Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, et al.: The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem 2005, 280:43243-43256.
• [41]Koldamova R, Staufenbiel M, Lefterov I: Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem 2005, 280:43224-43235.
• [42]Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM: Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem 2005, 280:43236-43242.
• [43]Hirsch-Reinshagen V, Wellington CL: Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer’s disease. Curr Opin Lipidol 2007, 18:325-332.
• [44]Schaefer EJ, Anderson DW, Zech LA, Lindgren FT, Bronzert TB, Rubalcaba EA, Brewer HB: Metabolism of high density lipoprotein subfractions and constituents in Tangier disease following the infusion of high density lipoproteins. J Lipid Res 1981, 22:217-228.
• [45]Schaefer EJ, Brousseau ME, Diffenderfer MR, Cohn JS, Welty FK, O’Connor J: Dolnikowski GG, Wang J, Hegele RA, Jones PJ: Cholesterol and apolipoprotein B metabolism in Tangier disease. Atherosclerosis 2001, 159:231-236.
• [46]Innerarity TL, Mahley RW: Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry 1978, 17:1440-1447.
• [47]Akanuma S, Ohtsuki S, Doi Y, Tachikawa M, Ito S, Hori S, Asashima T, Hashimoto T, Yamada K, Ueda K, et al.: ATP-binding cassette transporter A1 (ABCA1) deficiency does not attenuate the brain-to-blood efflux transport of human amyloid-beta peptide (1–40) at the blood–brain barrier. Neurochem Int 2008, 52:956-961.
• [48]Savage MJ, Trusko SP, Howland DS, Pinsker LR, Mistretta S, Reaume AG, Greenberg BD, Siman R, Scott RW: Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci 1998, 18:1743-1752.
• [49]Cirrito JR, May PC, O’Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, et al.: In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 2003, 23:8844-8853.
• [50]Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, Munoz B, Srinivasan K, Wang B, Robertson BJ, et al.: Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J Pharmacol Exp Ther 2005, 312:635-643.
• [51]Abramowski D, Wiederhold KH, Furrer U, Jaton AL, Neuenschwander A, Runser MJ, Danner S, Reichwald J, Ammaturo D, Staab D, et al.: Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther 2008, 327:411-424.
• [52]Patterson BW, Carraro F, Wolfe RR: Measurement of 15 N enrichment in multiple amino acids and urea in a single analysis by gas chromatography/mass spectrometry. Biol Mass Spectrom 1993, 22:518-523.
• [53]Patterson BW, Mittendorfer B, Elias N, Satyanarayana R, Klein S: Use of stable isotopically labeled tracers to measure very low density lipoprotein-triglyceride turnover. J Lipid Res 2002, 43:223-233.